Drug intelligence / Profile preview

KV-003

Development stage: Preclinical
Lead developer: Kinvard Bio
Modality: Small Molecules

Overview

KV-003 is a small molecule oxepanoprolinamide (OPP) antibiotic being developed by Kinvard Bio. It is designed to target the peptidyl transferase center (PTC) of the bacterial ribosome, thereby blocking protein synthesis and inhibiting bacterial growth. The drug is specifically being developed for the treatment of chronic respiratory infections, including non-tuberculous mycobacterial (NTM) lung disease caused by *Mycobacterium abscessus* (MAB) and *Mycobacterium avium complex* (MAC). As of early 2024, KV-003 is in the discovery stage of development.

Targets

PTC (50S ribosomal peptidyl transferase center)

Beyond the preview

Go deeper on KV-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KV-003.

Explore the full profile